1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Bal Pharma Limited

Bal Pharma Limited

81.70
INR
-2.87
(-3.39%)
4.57EPS
17.49P/E
1.27BMarket Cap
Bal Pharma Limited
NSE:BALPHARMA
(National Stock Exchange of India)

Recent

price

81.70

P/E

ratio

17.49

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
109.16
132.67
139.89
168.04
146.22
151.35
158.24
146.74
155.67
118.31
173.92
188.71
192.29
207.36
185.63
190.31
211.04
Revenue per Share
0.45
3.57
4.05
4.77
2.83
1.09
1.24
1.96
2.67
-8.62
3.34
3.79
1.64
4.7
4.55
3.95
4.55
Basic EPS, GAAP
8.04
8.84
11.23
5.5
6.96
-26.07
-1.3
-2.26
-0.59
12.83
13.36
12.36
-10.31
7.51
0.96
5.31
- -
Free Cash Flow per Basic Share
- -
- -
- -
0.87
1.18
1.18
1.19
1.19
1.04
1
- -
1
0.99
1
1.21
1.2
- -
Dividend per Share
34.82
37.88
42.2
45.04
42.88
44.04
44.06
45.86
47.02
36.99
36.15
37.65
40.66
45.56
48.63
51.65
- -
Book Value per Share
29.15
32.54
37.39
40.66
39.1
40.45
40.77
39.99
40.29
29.75
28.67
30.06
31.55
35.94
38.69
40.81
- -
Tangible Book Value per Share
10
11
11
11
13
13
14
14
14
14
14
15
16
16
16
16
16
Basic Weighted Avg Shares
1,144
1,397
1,479
1,789
1,872
1,948
2,243
2,080
2,206
1,677
2,469
2,797
3,017
3,263
2,943
3,030
3,344
Sales/Revenue/Turnover
6.42
7.67
8.39
7.34
5.78
4.03
3.71
5.08
5.23
-1.57
6.92
5.38
5.82
6.67
6.83
7.56
6.71
Operating Margin (%)
34
41
48
47
70
70
65
68
62
2
95
90
91
101
98
111
113
Depreciation Expense
5
38
43
51
36
14
18
28
38
-122
47
56
26
74
72
63
72
Net Income, GAAP
57.17
13.94
15.83
23.45
25.05
90.21
113.79
86.94
- -
- -
- -
37.87
44.84
17.7
- -
- -
- -
Effective Tax Rate (%)
0.41
2.69
2.9
2.84
1.94
0.72
0.78
1.34
1.72
-7.29
1.92
2.01
0.85
2.27
2.45
2.07
2.15
Profit Margin (%)
4
-18
4
83
128
148
213
304
198
16
116
189
188
311
154
130
- -
Working Capital
118
61
17
80
66
159
178
347
288
243
255
293
317
377
327
375
- -
LT Debt
365
401
446
500
552
565
601
602
602
453
534
585
637
720
774
823
- -
Total Equity
3.5
11.07
11.52
10.51
7.67
0.62
-0.76
0.84
- -
- -
- -
6.44
5.27
8.65
- -
- -
- -
Return on Invested Capital (%)
0.53
4.17
4.72
9.99
7.08
2.49
2.01
3.89
- -
- -
- -
6.68
4.59
8.74
- -
- -
- -
Return on Capital (%)
1.31
9.81
10.12
10.72
6.89
2.51
2.95
4.37
5.76
-20.52
8.95
10
4.2
10.89
9.66
7.87
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,291
- -
LT Borrowings
- -
319
- -
LT Finance Leases
- -
56
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
16
Market Capitalization
1,167
962
1,267

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,622
- -
Cash, Cash Equivalents & STI
- -
92
- -
Accounts Receivable, Net
- -
936
- -
Inventories
- -
1,164
- -
Total Current Liabilities
- -
2,492
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,291
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.49%
9.07%
6.26%
Free Cash Flow
-236.21%
0.28%
453.26%
Net Income, GAAP
-30.55%
27.26%
-12.91%
Sales/Revenue/Turnover
5.96%
4.49%
2.96%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
744
737
732
819
2,943
2026
659
740
877
841
3,030
2027
886
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.16
0.65
0.33
3.4
4.55
2026
0.13
0.45
1.12
2.26
3.95
2027
0.71
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1.21
2026
- -
- -
- -
- -
1.2
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Bal Pharma Limited is an integrated pharmaceutical company headquartered in Bangalore, India, specializing in the manufacturing and marketing of active pharmaceutical ingredients (APIs), pharmaceutical formulations, and finished dosage forms. The company’s product portfolio includes prescription drugs, generic medicines, over-the-counter (OTC) products, intravenous infusion products, Ayurvedic medicines, bulk actives, and pharmaceutical intermediates. It operates multiple manufacturing units across India, including specialized API production facilities and formulation plants. Therapeutic focus areas encompass anti-diabetes, anti-histamine, anti-inflammatory, gastroenterology, cardiology, dermatology, respiratory care, women's health, anti-infectives, pain management, skin care, bone health, and cardiac care. Notable brands include Stonex, Ashwamed, Prostowin, Suswas, Menoleap, Ayursulin in the Ayurvedic segment; Secremet and Servace for cardiac care; and Diabend and Sitabend for diabetic care. The company has a strong presence in domestic and international markets, supplying to over 80 countries, including non-regulated, semi-regulated, and increasingly regulated markets. Recent major developments include the commencement of a greenfield API project at Kadechur KIADB Industrial Area in Yadgir District, Karnataka, aimed at expanding its bulk drug manufacturing capacity. In 2023, Bal Pharma launched Sitagliptin-based products under the brand names SITABEND and SITABEND-M, strengthening its diabetic care portfolio. The company completed the merger with Golden Drugs Private Limited, enhancing its manufacturing and operational scale. Bal Pharma is focused on vertical integration with investments in multiple facilities including IV units, API production, and formulation units at Pune, Bangalore, Rudrapur, and Sangli. These expansions aim to enhance production capabilities and support its strategic growth in both domestic and international pharmaceutical sectors. Founded in 1987, Bal Pharma continues to invest in innovative solutions and product diversification within the pharmaceutical industry while maintaining a commitment to providing high-quality, safe, and affordable medicines.